Tenaya Therapeutics, Inc. Share Price
NASDAQ: TNYA | Micro CapTenaya Therapeutics, Inc. Stock Performance
Open $0.75 | Prev. Close $0.75 | Circuit Range N/A |
Day Range $0.74 - $0.76 | Year Range $0.53 - $2.31 | Volume 5,674 |
Average Traded $0.75 |
Tenaya Therapeutics, Inc. Share Price Today
As of 11 August 2026, Tenaya Therapeutics, Inc.'s share price is $0.76. The stock opened at $0.75, compared to its previous close of $0.75. During today's trading session, Tenaya Therapeutics, Inc.'s share price traded between $0.74 and $0.76, with an average price of $0.75. Over the past 52 weeks, the stock has recorded a high of $2.31 and a low of $0.53. In terms of performance, Tenaya Therapeutics, Inc.'s share price has risen by 35.41% over the last six months and is down 32.36% on a year-on-year basis.
Tenaya Therapeutics, Inc. Share Price Chart
Tenaya Therapeutics, Inc. Stock Fundamentals & Key Indicators
Market Cap $116.41M | PE Ratio (TTM) -1.29 | Dividend Yield N/A |
EPS (TTM) $-0.59 | Revenue (TTM) N/A | Return On Equity (TTM) -73.50% |
Profit Margin N/A | Debt to Equity 0.13 | Quarterly Earnings Growth YoY 20.91% |
Tenaya Therapeutics, Inc. Quarterly Profit & Loss
All figures in USD
Tenaya Therapeutics, Inc. Annual Profit & Loss
All figures in USD
About Tenaya Therapeutics, Inc.
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. The company's lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in phase 2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in phase 1 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. The company develops its products through gene editing, cellular regeneration, gene silencing, and gene addition. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Tenaya Therapeutics, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $0.74 | $0.76 | +1.60% |
Jul 2026 | $0.74 | $0.75 | +2.74% |
Jun 2026 | $0.90 | $0.73 | -17.25% |
May 2026 | $0.69 | $0.88 | +26.22% |
Apr 2026 | $0.70 | $0.70 | +0.43% |
Mar 2026 | $0.56 | $0.69 | +23.67% |
Feb 2026 | $0.78 | $0.56 | -27.39% |
Jan 2026 | $0.71 | $0.77 | +9.79% |
Dec 2025 | $1.31 | $0.70 | -49.46% |
Nov 2025 | $1.50 | $1.40 | -4.45% |
Oct 2025 | $1.59 | $1.46 | -10.43% |
Sep 2025 | $1.10 | $1.63 | +44.89% |
TNYA Share Price FAQs
What is Tenaya Therapeutics, Inc. share price today?
What is the 52 week high and 52 week low of Tenaya Therapeutics, Inc. stock?
What is TNYA's market capitalisation today?
What is TNYA's net income for the last quarter?
What is the 5 year returns of TNYA?
What is the high & low stock price of TNYA today?
Can I buy TNYA shares in India?